Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izaf304 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Yan-Jiun Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, 110, Taiwan. Hauptthemen laut MEDLINE: Aspirin, Colorectal Neoplasms, Inflammatory Bowel Diseases, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: The Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital.
Abstract (Originalsprache)
Background
Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC). However, the chemopreventive role of aspirin remains uncertain due to conflicting findings in prior studies.
Methods
The study sought to evaluate the association between long-term aspirin use and the risk of CRC and all-cause mortality in patients with IBD. We conducted a nationwide propensity score–matched cohort study using Taiwan’s National Health Insurance Research Database and Cancer Registry from 2008 to 2022. Time-dependent Cox models and Fine and Gray competing risk models were applied.
Results
Among 2743 matched aspirin users and 2743 nonusers, aspirin use was associated with reduced CRC risk (adjusted hazard ratio, 0.42; 95% confidence interval, 0.31-0.57) and lower all-cause mortality (adjusted hazard ratio, 0.66; 95% confidence interval, 0.58-0.74). A dose-response relationship was found for cumulative exposure, while optimal daily intensity was near 80 mg/d.
Conclusions
Long-term use of low-to-moderate-dose aspirin was associated with reduced risks of CRC and mortality in patients with IBD. These findings support aspirin’s potential as a chemopreventive agent and justify further randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, 110, Taiwan.
- Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.
- Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, 110, Taiwan.
- Department of Anesthesiology, School of Medicine, Chung Shan Medical University, Taichung, 40201, Taiwan.
- Department of Anesthesiology, Chung Shan Medical University Hospital, Taichung, 40201, Taiwan.
- Center for Regional Anesthesia and Pain Management, Chung Shan Medical University, Taichung, 40201, Taiwan.
ORCID-Profile: Yan-Jiun Huang, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
Förderung
- The Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital
Zitieren
APA
Huang, Y. J., Lin, J. A., Chen, W. M., Shia, B. C., & Wu, S. Y. (2026). Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf304
Vancouver
Huang YJ, Lin JA, Chen WM, Shia BC, Wu SY. Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf304
BibTeX
@article{Huang2026,
author = {Huang, Yan-Jiun and Lin, Jui-An and Chen, Wan-Ming and Shia, Ben-Chang and Wu, Szu-Yuan},
title = {Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izaf304}
}
EUVIMED